Web2 mrt. 2024 · Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing … Web6 feb. 2024 · Huahui Health Investigators None specified. Study Documents (Full-Text) None provided. More Information Publications None provided. Responsible Party: Huahui Health ClinicalTrials.gov Identifier: NCT05713318 Other Study ID Numbers: HH120-NS215 First Posted: Feb 6, 2024 Last Update Posted: Feb 6, 2024 Last Verified: Feb 1, 2024
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ...
Web8 jan. 2024 · Latest HUAHUI HEALTH LTD. Patents: Anti-pre-S1 HBV antibodies A METHOD OF TREATING HBV INFECTION BY USING ANTI-PRE-S1 HBV ANTIBODIES ANTI-FGF19 ANTIBODIES POLYMERIC BILE ACID DERIVATIVES INHIBIT HEPATITIS B AND D VIRUS AND NTCP TRANSPORT Skip to:Description · Claims · References … Web21 aug. 2024 · Huahui Health Announces Late-Breaking Data for Its Investigational Anti-PreS1 HBV Neutralizing Antibody at the AASLD 2024. View details; 2024-10-28. HH … Prior to Huahui Health, Dr. Ye played multiple leading roles during drug … HH-003 is a novel entry inhibitor for HBV & HDV. It has the potential to become a … Huahui Health Announces Late-Breaking Data for Its Investigational Anti-PreS1 … Huahui Health Ltd. and its affiliates are the controllers of your personal information. … Tel:010-80766688 Email: [email protected]. Floor 7-8, Building 5, No.9 Yike Road, … Tel:010-80766688 Email: [email protected]. Floor 7-8, Building 5, No.9 Yike Road, … 2024-11-08. 华辉安健在研乙肝新药hh-003在美国肝病研究学会2024年会上公 … brow lounge robinsons magnolia
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics …
Web9 mrt. 2024 · HUAHUI HEALTH (AUS) PTY LTD (ACN: 653385972) was incorporated on 03/09/2024 in Australia. Their business is recorded as Australian Proprietary Company, … Web11 mrt. 2024 · Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal antibody in healthy volunteers, and to determine its pharmacokinetic profile and immunogenicity. Detailed Description: Web12 dec. 2024 · Abstract: A method for treating HBV infection in a subject, comprising administering to the subject an anti-pre-S1 antibody or a fragment thereof at a dose of … browlounge phone